APGE
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Apogee Therapeutics Inc (APGE) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | D+ (1.7) | C+ (2.7) | C+ (2.5) | C+ (2.6) | C (2.4) |
| 2026-11-10 | C+ (2.5) | D+ (1.7) | C+ (2.7) | C+ (2.5) | F (0.0) | C- (1.9) |
| 2026-11-03 | C+ (2.5) | D+ (1.6) | C+ (2.7) | C+ (2.5) | F (0.0) | C- (1.9) |
| 2026-10-27 | C+ (2.5) | D+ (1.6) | C+ (2.7) | C+ (2.5) | F (0.0) | C- (1.9) |
| 2026-10-20 | C+ (2.5) | D+ (1.6) | C+ (2.7) | C+ (2.5) | F (0.0) | C- (1.9) |